Literature DB >> 6184439

IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells.

E Razin, J M Mencia-Huerta, R L Stevens, R A Lewis, F T Liu, E Corey, K F Austen.   

Abstract

Mouse bone marrow-derived mast cells differentiated in vitro and sensitized with monoclonal IgE respond to antigen-initiated activation with the release of histamine, beta-hexosaminidase, chondroitin sulfate E proteoglycan, and leukotriene C4 (LTC4). The chondroitin sulfate E nature of the glycosaminoglycan side chain was established by demonstrating that the chondroitinase ABC disaccharide digestion products were composed of equal quantities of 4-sulfated and 4,6-disulfated N-acetyl-galactosamine. The single immunoreactive sulfidopeptide leukotriene, released and quantitated with a class-specific antibody, was identified as LTC4 by its retention time on reverse-phase high-performance liquid chromatography and by its specific spasmogenic activity on the guinea pig ileum. The release of the preformed mediators, as well as of LTC4, was related in a dose-response fashion to the concentration of monoclonal IgE used during the sensitization step and to the concentration of specific antigen used to initiate the activation-secretion response. The optimal concentrations of IgE for sensitization and of antigen for challenge were the same for the release of preformed mediators and of LTC4. In addition, the time courses of their release were superimposable, with a plateau at 5 min after antigen challenge. The release of three preformed mediators and of LTC4 after fixation of IgE, washing of the sensitized cells, and antigen challenge unequivocally indicates a bone marrow-derived mast cell origin for these products. Linear regression analyses of the net percent release of beta-hexosaminidase to histamine and of 35S-chondroitin sulfate E to beta-hexosaminidase yielded straight lines that intersected at the origin, which indicates that the three preformed mediators are localized in the secretory granules of the bone marrow-derived mast cells. The concomitant generation of 23 ng of LTC4/10(6) sensitized bone marrow-derived mast cells represents the first example of IgE-dependent release of substantial amounts of LTC4, a component of slow reacting substance of anaphylaxis, from a mast cell population of greater than 95% purity. The IgE-dependent generation of LTC4, rather than prostaglandin D2, by the chondroitin sulfate E proteoglycan-containing bone marrow-derived mast cells contrasts with the predominant generation of prostaglandin D2 by heparin proteoglycan-containing mast cells. These differences together support the existence of two phenotypically different mast cell subclasses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184439      PMCID: PMC2186907          DOI: 10.1084/jem.157.1.189

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

1.  Increased sensitivity of the enzymatic isotopic assay of histamine: measurement of histamine in plasma and serum.

Authors:  R E Shaff; M A Beaven
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

2.  The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock.

Authors:  W E BROCKLEHURST
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

3.  Identification of a component of rat mononuclear cell SRS as leukotriene D.

Authors:  M K Bach; J R Brashler; S Hammarström; B Samuelsson
Journal:  Biochem Biophys Res Commun       Date:  1980-04-29       Impact factor: 3.575

4.  Studies on the exocytosis of cultured mast cells derived from mouse bone marrow.

Authors:  E Razin; A Cordon-Cardo; C R Minick; R A Good
Journal:  Exp Hematol       Date:  1982-07       Impact factor: 3.084

5.  Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization.

Authors:  F T Liu; J W Bohn; E L Ferry; H Yamamoto; C A Molinaro; L A Sherman; N R Klinman; D H Katz
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

6.  Generation of leukotriene C4 from a subclass of mast cells differentiated in vitro from mouse bone marrow.

Authors:  E Razin; J M Mencia-Huerta; R A Lewis; E J Corey; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

7.  N-Acetyl-beta-glucosaminidases in human spleen.

Authors:  D Robinson; J L Stirling
Journal:  Biochem J       Date:  1968-04       Impact factor: 3.857

8.  Binding properties of IgE receptors on normal mouse mast cells.

Authors:  A R Sterk; T Ishizaka
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

9.  Inhibition of leukotriene C and leukotriene D biosynthesis.

Authors:  L Orning; S Hammarström
Journal:  J Biol Chem       Date:  1980-09-10       Impact factor: 5.157

10.  Dynamics of leukotriene C production by macrophages.

Authors:  C A Rouzer; W A Scott; A L Hamill; Z A Cohn
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  46 in total

1.  Vav1 regulates phospholipase cgamma activation and calcium responses in mast cells.

Authors:  T S Manetz; C Gonzalez-Espinosa; R Arudchandran; S Xirasagar; V Tybulewicz; J Rivera
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Stem cell factor enhances immunoglobulin E-dependent mediator release from cultured rat bone marrow-derived mast cells: activation of previously unresponsive cells demonstrated by a novel ELISPOT assay.

Authors:  P B Hill; A J MacDonald; E M Thornton; G F Newlands; S J Galli; H R Miller
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Pulmonary epithelial cancer cells and their exosomes metabolize myeloid cell-derived leukotriene C4 to leukotriene D4.

Authors:  Ana Lukic; Jie Ji; Helena Idborg; Bengt Samuelsson; Lena Palmberg; Susanne Gabrielsson; Olof Rådmark
Journal:  J Lipid Res       Date:  2016-07-19       Impact factor: 5.922

4.  Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP.

Authors:  W F Owen; J Petersen; K F Austen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 5.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

Review 6.  Potential effector and immunoregulatory functions of mast cells in mucosal immunity.

Authors:  L L Reber; R Sibilano; K Mukai; S J Galli
Journal:  Mucosal Immunol       Date:  2015-02-11       Impact factor: 7.313

7.  Interleukin 4 suppresses c-kit ligand-induced expression of cytosolic phospholipase A2 and prostaglandin endoperoxide synthase 2 and their roles in separate pathways of eicosanoid synthesis in mouse bone marrow-derived mast cells.

Authors:  M Murakami; J F Penrose; Y Urade; K F Austen; J P Arm
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

8.  Impact of actin rearrangement and degranulation on the membrane structure of primary mast cells: a combined atomic force and laser scanning confocal microscopy investigation.

Authors:  Zhao Deng; Tiffany Zink; Huan-yuan Chen; Deron Walters; Fu-tong Liu; Gang-yu Liu
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

9.  The antigen presentation function of bone marrow-derived mast cells is spatiotemporally restricted to a subset expressing high levels of cell surface FcepsilonRI and MHC II.

Authors:  Jian Gong; Ning-Sun Yang; Michael Croft; I-Chun Weng; Liangwu Sun; Fu-Tong Liu; Swey-Shen Chen
Journal:  BMC Immunol       Date:  2010-06-30       Impact factor: 3.615

10.  Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Authors:  Patrice Dubreuil; Sébastien Letard; Marco Ciufolini; Laurent Gros; Martine Humbert; Nathalie Castéran; Laurence Borge; Bérengère Hajem; Anne Lermet; Wolfgang Sippl; Edwige Voisset; Michel Arock; Christian Auclair; Phillip S Leventhal; Colin D Mansfield; Alain Moussy; Olivier Hermine
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.